NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Extinguishment of 87050 Equity Shares bought under Buy-back06-04-2023
06-04-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate06-04-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 06, 2023. Total no. of equity shares bought back are 006-04-2023
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended 31st March 202305-04-2023
Natco, MacLeods to launch their versions of Bedaquiline
Bedaquiline is J&J's breakthrough TB drug; patent to expire in July03-04-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 03, 2023. Total no. of equity shares bought back are 430003-04-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on March 31, 2023. Total no. of equity shares bought back are 031-03-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate30-03-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought-back on March 28, 2023 are 445028-03-2023